This is the online version of AASLD in 30 Seconds, the latest from the American Association for the Study of Liver Diseases’s Liver Meeting. Sign up here to get it in your inbox.
Good morning. D.C.’s first big cold snap rolled in overnight! RIP to the backyard gardens. Grab a hot bev, and let’s get into the latest liver news.
Rezdiffra updates to tide us over until 2027
Sunday brought new data from key event sponsor Madrigal about its MASH drug resmetirom, the daily pill sold under the brand name Rezdiffra, which was granted accelerated FDA approval last year. Crucial information about the drug’s effects on outcomes like MELD score and liver-related mortality are still to come — topline results from MAESTRO-NASH OUTCOMES are due in 2027. In the meantime, Sunday’s oral presentation highlighted the need for MASH patients to get consistent treatment in order to hold onto benefits.
